ESC Congress 24 – Day 4 of the ESC Congress 2024 was filled with hot line and late-breaking data poised to influence cardiovascular practice.

Interventional experts Dr Mirvat Alasnag and Dr Khaled Al-Shaibi (King Fahd Armed Forces Hospital, SA) joined us to review and distil the key messages from the latest data presented at the last of the biggest cardiovascular event of 2024.

Day 4 Highlights:

00:19-04:50: INFINITY-SWEDEHEART: Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes

05:01-07:42: OCCUPI: Optical coherence tomography-guided coronary intervention in patients with complex lesions

07:54 – 12:10: REC-CAGEFREE I: Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions: a multicenter, non-inferiority trial

12:27-14:57: AEGIS-II: Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction

14:59 – 15:45: Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial

Recorded on-site at the ESC Congress 2024, London.

Editors: Mirjam Boros and Jordan Rance.

Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles, David Ben-Harosh.

Support: This is an independent discussion produced by Radcliffe Cardiology.

Visit Radcliffe Cardiology: [ Ссылка ]
Visit Radcliffe Vascular: [ Ссылка ]

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: [ Ссылка ]
Follow us on X: [ Ссылка ]

свернуть